Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
F 1.50 -1.32% -0.02
APTO closed down 1.32 percent on Monday, March 18, 2024, on 46 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 26
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -1.32%
Lower Bollinger Band Walk Weakness -1.32%
Wide Bands Range Expansion -1.32%
Lower Bollinger Band Touch Weakness -1.32%
Oversold Stochastic Weakness -1.32%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Rose Above Previous Day's High about 21 hours ago
2x Volume Pace about 21 hours ago
1.5x Volume Pace about 21 hours ago
Down 3% about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aptose Biosciences, Inc. Description

Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Drugs Immunotherapy Oncology Acute Myeloid Leukemia Pancreatic Cancer Targeted Therapy Cancer Therapies Hematologic Malignancies Bacterial Infections Treatment Of Acute Myeloid Leukemia Bemcentinib Small Molecule Therapies Preclinical Stage Product Gemcitabine Phosphoinositide 3 Kinase Inhibitor Stage Products Preclinical Stage Products Treatment Of Pancreatic Cancer Drug Resistant Bacterial Infections

Is APTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.125
52 Week Low 1.36
Average Volume 95,503
200-Day Moving Average 3.17
50-Day Moving Average 1.94
20-Day Moving Average 1.71
10-Day Moving Average 1.57
Average True Range 0.14
RSI (14) 33.77
ADX 32.14
+DI 9.32
-DI 25.16
Chandelier Exit (Long, 3 ATRs) 1.67
Chandelier Exit (Short, 3 ATRs) 1.77
Upper Bollinger Bands 2.05
Lower Bollinger Band 1.38
Percent B (%b) 0.18
BandWidth 39.05
MACD Line -0.14
MACD Signal Line -0.13
MACD Histogram -0.018
Fundamentals Value
Market Cap 23.56 Million
Num Shares 15.7 Million
EPS -7.72
Price-to-Earnings (P/E) Ratio -0.19
Price-to-Sales 0.00
Price-to-Book 4.10
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.60
Resistance 3 (R3) 1.60 1.57 1.58
Resistance 2 (R2) 1.57 1.54 1.57 1.58
Resistance 1 (R1) 1.53 1.53 1.52 1.53 1.57
Pivot Point 1.50 1.50 1.49 1.50 1.50
Support 1 (S1) 1.47 1.48 1.45 1.47 1.43
Support 2 (S2) 1.44 1.46 1.44 1.42
Support 3 (S3) 1.40 1.44 1.42
Support 4 (S4) 1.40